Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 20, 2023 | $1.51 | 2023-10-20 | 2023-10-16 |
Dividends Summary
- Consistent Payer: has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held TRML shares during this period received a total of $1.51 per share in dividend income.
- Latest Payout: The most recent dividend of $1.51/share was paid 826 days ago, on October 20, 2023.
Company News
Over 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.
Law firm Monteverde & Associates is investigating potential legal actions related to several corporate mergers and acquisitions involving Tourmaline Bio, Pinnacle Financial Partners, Monroe Capital, and Union Pacific.
Novartis will present new clinical data on Pluvicto and Kisqali at the ESMO Congress 2025, showcasing potential advancements in prostate and breast cancer treatments with promising long-term insights into disease management.
Law firm Monteverde & Associates is investigating the proposed sale of Tourmaline Bio to Novartis, where shareholders will receive $48.00 per share, to determine if the transaction is fair.
Novartis announced a $1.4 billion acquisition of Tourmaline Bio, paying $48 per share in cash. The deal focuses on Tourmaline's lead drug pacibekitug, an investigational antibody targeting systemic inflammation in cardiovascular disease.
